U.S. markets closed
  • S&P 500

    4,471.37
    +33.11 (+0.75%)
     
  • Dow 30

    35,294.76
    +382.20 (+1.09%)
     
  • Nasdaq

    14,897.34
    +73.91 (+0.50%)
     
  • Russell 2000

    2,265.65
    -8.52 (-0.37%)
     
  • Gold

    1,768.10
    -29.80 (-1.66%)
     
  • EUR/USD

    1.1606
    +0.0005 (+0.0464%)
     
  • 10-Yr Bond

    1.5760
    +0.0570 (+3.75%)
     
  • Vix

    16.30
    -0.56 (-3.32%)
     
  • GBP/USD

    1.3751
    +0.0074 (+0.5418%)
     
  • USD/JPY

    114.2000
    +0.5230 (+0.4601%)
     
  • BTC-USD

    60,895.46
    -497.64 (-0.81%)
     
  • CMC Crypto 200

    1,464.06
    +57.32 (+4.07%)
     
  • FTSE 100

    7,234.03
    +26.32 (+0.37%)
     
  • Nikkei 225

    29,068.63
    +517.70 (+1.81%)
     

Halberd Corporation Discusses the Development of New Class of COVID-19 Antibody with The Stock Day Podcast

  • Oops!
    Something went wrong.
    Please try again later.
·7 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Phoenix, Arizona--(Newsfile Corp. - October 22, 2020) - The Stock Day Podcast welcomed Halberd Corporation (OTC Pink: HALB) ("the Company"), a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. CEO of the Company, Bill Hartman, joined Stock Day host Everett Jolly.

Jolly began the interview by asking about Hartman's transition from his former position as the CEO of Premier Biomedical to his current position as the CEO of Halberd Corporation. Hartman shared that Premier Biomedical remained active as an R&D company for many years, but struggled to recuperate from debt. Hartman's partner Dr. Mitchell Felder eventually left Premier Biomedical and his technology was sold to Halberd Corporation. "They contacted me and asked me to go with them because they wanted my experience," explained Hartman, who initially declined the offer. "I cherry-picked the best people from Premier Biomedical and brought them over to Halberd," he shared. "The beauty of Halberd is that they're debt-free."

"We've got the best people, we've got established technology, and it's been an absolute great move, and we've had tremendous success," said Hartman.

Jolly then commented on the Company's increasing stock price, which has risen significantly over the past week. "It took us a while to completely flesh-out our organization," said Hartman. "You can't rush excellence," he added. "We looked around the industry for a university partner. After a careful selection process, we selected Arizona State University (ASU) because they have the best capability," said Hartman.

"Working with ASU, we've developed a unique antibody against COVID-19, and we've also developed an entirely new class of antibody against COVID-19. We are filing patent applications for both of these," said Hartman. "Just forecasting this via press releases we have seen a tremendous increase in our stock price. We were up 1,000% in eight days."

"Among our products is a nasal spray that is possibly an alternative to a COVID-19 vaccine," shared Hartman, noting the controversy surrounding the development of a COVID-19 vaccine. "We've just indicated that through press releases and that's what has really driven our increase."

Jolly then noted the Company's low market cap. "That's because of the stock price," explained Hartman. "We have a low float, we're debt free, and we have tremendous people, and tremendous technology that is already developed," said Hartman, before adding that the Company's methodology for treating disease is not limited to COVID-19. "We've proven in the laboratory that we have a potential cure for PTSD, among other conditions," said Hartman, adding that the Company's treatment solutions eliminate the negative side effects associated with current treatments on the market.

"Where do you see the future of your technology in two to three quarters, as well as your stock price?" asked Jolly. Hartman shared that the Company needs to prove their value to the market, but remains confident in their potential. "All I can say is that we're working very hard. We've got a great team, great technology, and a great partner now in Arizona State University."

"We also have a team in South America, and have access to Asia," said Hartman, adding that the Company is also working towards expanding into Europe. "We see our products and our technology going worldwide," he shared.

"I see us preserving the company. We may end up in joint ventures, but we're not going to lose our identity because we have too many things going," said Hartman, before elaborating on the Company's anti-addiction patch. "We have a lot of new products and we're frankly very excited for the company and its future."

To close the interview, Hartman expressed his confidence and excitement for the Company's potential as they continue to move forward. He also encouraged shareholders to stay up-to-date on the Company's latest press releases and projects. "What I want listeners to take away is that we're a great company that is debt-free and offers a lot of technology and a lot of connections. You're gonna hear a lot about Halberd in the future."

To hear Bill Hartman's entire interview, follow the link to the podcast here: https://audioboom.com/posts/7711959-halberd-corporation-discusses-the-development-of-new-class-of-covid-19-antibody-with-the-stock-da

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/

About Halberd Corporation.

Halberd Corporation. (OTC Pink: HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Halberd's Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company's Articles of Incorporation here. The number of outstanding shares remains at 317,721,539.

The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: "Method for Treating and Curing Covid-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus", and, "Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans." Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -

On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.

SOURCE:

Stock Day Media
(602) 821-1102

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66617